SCHEMBL30288951

SCHEMBL30288951

CC(C)(C)OC(=O)NC1CCC(CN2CCN(C(=O)OCc3ccccc3)CC2=O)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 4/20 0.52
PDE4B Q07343 1/20 0.45
KMT2A Q03164 3/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
USP19 O94966 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
DPP4 P27487 1/20 0.42
KCNH2 Q12809 1/20 0.42
DPP7 Q9UHL4 1/20 0.42
TSHR P16473 1/20 0.41
HTT P42858 1/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KDM1A O60341 1/20 0.41
MAOB P27338 1/20 0.41
KCNA3 P22001 1/20 0.41
DRD3 P35462 1/20 0.41
MEN1 O00255 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4385886 0.86 SMN1; SMN2 (0.50) USP19HTTNPC1RAB9ASMN1; SMN2
SCHEMBL27224954 0.86 DRD2 (0.59) DRD2PDE4BKMT2AL3MBTL1ALDH1A1
SCHEMBL7657420 0.86 SMN1; SMN2 (0.50) USP19HTTNPC1RAB9ASMN1; SMN2
SCHEMBL20339027 0.83 PARP1 (0.46) PDE4BKMT2AUSP19HTTNPC1
SCHEMBL27039636 0.82 DRD2 (0.49) DRD2PDE4BKMT2AL3MBTL1ALDH1A1
SCHEMBL28429223 0.81 USP19 (0.55) KMT2AUSP19NPC1RAB9ASMN1; SMN2
SCHEMBL951538 0.81 KMT2A (0.59) PDE4BKMT2AL3MBTL1ALDH1A1GAA
SCHEMBL25426557 0.81 SMN1; SMN2 (0.45) KMT2AL3MBTL1USP19HTTNPC1
SCHEMBL27039446 0.81 DRD2 (0.48) DRD2PDE4BKMT2AL3MBTL1ALDH1A1
SCHEMBL28437662 0.81 USP19 (0.56) KMT2AUSP19NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4405359-A2 MDM2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-07-31 EP disclosed
WO-2023049790-A2 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-03-30 WO disclosed